IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Clobazam For Temporal Lobe Epilepsy: Reviewing Pharmacology, Efficacy, And Challenges

Author: - Gondaliya Isha Aniruddha Kumar

Institute: - Gyanmanjari Innovative University

Department: Department of science

Branch:- B.Sc. Microbiology Hons Bioinformatics

India, Gujarat, Bhavnagar

1. Abstract

Epilepsy, a type of neurological disorder marked by recurrent seizures, results from abnormal electrical activity in the human brain (**38).** Temporal Lobe Epilepsy (TLE), a type of focal epilepsy, represents one of the most common forms of epilepsy, with seizures originating from the temporal lobes. Clobazam (C16H13ClN2O2), a benzodiazepine anticonvulsant, is frequently used in managing TLE, particularly in cases that are resistant to other treatments **(2, 13)**. This review paper discusses the role of clobazam in TLE, its pharmacological properties and effects, clinical efficiency, and associated challenges. It also explores the methodologies employed in drug analysis, including techniques such as reversed-phase high-performance liquid chromatography (HPLC) **(12, 4, 1)** and mass spectrometry, which helps in ensuring the drug's purity and efficacy **(1, 22)**. It also talks about the drug's mode of action on humans, i.e., by GABA receptor action **(7)**.

Keywords

Temporal lobe Epilepsy, Focal epilepsy, Benzodiazepine, Clobazam, anticonvulsant

2. Introduction

It is a common brain condition where a person gets abnormal seizure strokes without warning **(36)**. Among 60% of all epilepsy cases, focal epilepsy is major **(36).** Temporal Lobe Epilepsy (TLE), a type of focal epilepsy that is particularly common and arises due to abnormal electrical discharges in the temporal lobes of the brain **(43).** These seizures can manifest with varying symptoms, including loss of consciousness or abnormal jerking movements **(43, 38).** The administration of TLE frequently requires pharmacological medications **(6)**, with clobazam rising as one of the foremost broadly utilised drugs, particularly for patients who show resistance to customary medicines **(8, 18).**

2.1 Significance

The significance of discussing TLE and its management lies in the increasing number of individuals affected by epilepsy **(9, 5, 43)**. Understanding the clinical efficiency of clobazam, as well as its advantages and disadvantages, is crucial for improving patient outcomes. This review serves to highlight the importance of raising awareness about the disease and the treatment options available while also providing a detailed look into the pharmacological properties of clobazam.

2.2 Objective

The primary objective of this review is to assess the therapeutic role, safety, and effectiveness of clobazam in treating TLE. It aims to examine its pharmacological mechanisms **(8, 6, 19),** clinical outcomes, and potential advantages over other antiepileptic drugs in managing this condition.

3. Temporal Lobe Epilepsy: An Overview

An overview of Temporal Lobe Epilepsy is a type of focal epilepsy that originates from the temporal lobes and is also known as partial epilepsy. It is responsible for a large proportion of cases of epilepsy and is usually diagnosed based on electrophysiological data in conjunction with neuroimaging methods.

3.1 Electrophysiological Data

One of the key diagnostic tools for TLE is electroencephalography (EEG) **(5)**. The abnormal electrical discharges that characterize TLE can be classified into:

Interictal Spikes: Brief waves that are sharp, show in between seizures **(5)**.

Ictal Discharges: Patterns of electrical activity observed during a seizure **(5)**.

EEG is instrumental in recognizing as well as tracking such aberrant electrical activity in TLE patients and offers useful data for diagnostic as well as treatment planning **(4, 5)**.

3.2 Neuroimaging

In addition to EEG, neuroimaging techniques such as magnetic resonance imaging (MRI) are invaluable in the diagnosis and management of TLE **(6)**. MRI scans can detect structural abnormalities in the temporal lobes, identifying the precise areas where seizures originate **(4)**. Functional MRI can also provide insights into brain activity during specific tasks, which can assist in planning surgical interventions when necessary **(24, 32, 38)**.

4. Clobazam in TLE Treatment



Fig – 1:-7-chloro-1-methyl-5-phenyl-1H-1, 5-benzodiazepine-2, 4(3H,5H) -di-one

Clobazam is a derivative of benzodiazepine administered as an adjunct for treating TLE **(9, 21, 26)**, particularly in drug-resistant cases. Its mechanism of action is to facilitate GABAergic inhibition in the brain to suppress aberrant neuronal firing and lessen seizure frequency **(7, 35)**. Clobazam is widely accepted for its effectiveness, though it comes with a set of advantages, disadvantages, and potential side effects **(11, 27)**.

4.1 Mechanism of Action



Fig. 2 Mode of action of clobazam in humans



Fig. -3: pathway of CLB metabolism in humans

4.2 Pharmacokinetics and Pharmacodynamics

Clobazam is rapidly absorbed upon oral administration and reaches peak plasma concentrations within 1 to 4 hours. It is liver-metabolised with active metabolite, or clobazam, being responsible for the anticonvulsive action. The medication shows a relatively long half-life of 8 to 20 hours, enabling long-term seizure control. The non-sedating action of clobazam, along with the longer half-life, makes this medication more favourable in controlling chronic seizure disorders such as TLE. **(12, 39, 40, 42).**

4.3 Advantages and Disadvantages

4.3.1 Advantages:

Clobazam is effective in decreasing seizure frequency in drug-resistant epilepsy, particularly TLE. It is generally tolerated with less in comparison to other AEDS. **(10, 13)**. Because of their less sedating action and their essentially identical efficacy in comparison with other drugs

The drug has a relatively favourable side effect profile, with sedation being less pronounced than other benzodiazepines **(10, 13).**

CLB is being used very frequently as an add-on treatment when polytherapy would be warranted, particularly in intractable epilepsy. Clobazam is associated with abuse and dependency potentials, especially with long-term usage. **(10, 13)**

Clobazam can be used in combination with other antiepileptic drugs, enhancing its therapeutic effect in difficult-to-treat cases **(26, 30).**

4.3.2 Disadvantages:

Common side effects include dizziness, hyperactivity, drowsiness, and mild cognitive impairment **(11)**.

Long-term use may lead to tolerance, requiring dose adjustments **(2, 22).**

Clobazam carries a risk of abuse and dependency, particularly with long-term use.

(11, 27).

While effective for many patients, it is not typically the first-line treatment for TLE.

5. Methodologies for Clobazam Analysis

To ensure the safety, quality, and efficacy of clobazam in clinical use, various analytical methods are employed to monitor its presence and concentration in pharmaceutical formulations and biological samples **(12, 4, 22).**

5.1. Reversed-phase high-performance liquid Chromatography



***Fig. 4 RP-HPLC techniques for analysis of peptide and protein* (12)**

This technique is very important for the separation and quantitation of clobazam from biological and pharmaceutical matrices. RP-HPLC operates with a non-polar stationary phase and a polar mobile phase, allowing the detection of clobazam and its metabolites with high sensitivity and precision. **(12, 4)**.

5.2 Mass Spectrometry (MS):

Another common technique for analyzing clobazam is mass spectrometry, which allows the determination of molecular structure, molecular weight, and molecular purity. This tool is especially significant for the identification of impurities or degradation products that may have an impact on the safety and efficacy of the drug. MS provides detailed information on the drug's molecular composition, which is crucial for quality control in drug manufacturing. **(1,4)**.



Fig. -5 mass spectroscopy methodology analysis for clobazam testing

6. Conclusion

Temporal Lobe Epilepsy, especially in drug-resistant patients. Such is the enormity of side effects, which implies that it is a conditional remedy for treatment with lots of proven benefits in the reduction of the quantity of fits conventional goods, and better quality of life for lots. Although it is not the first line of treatment, clobazam is an effective adjunct in the treatment of TLE **(10, 13, 3, 18, 19, 20, 21, 31, 33).**

7. Reference

1) Aguilar, M. I. (2004). *Reversed-phase high-performance liquid chromatography*. In M. I. Aguilar (Ed.), *HPLC of peptides and proteins* (Vol. 251, pp. 1–27). Springer.
2) Barcs, G., & Halasz, P. (1996). Effectiveness and tolerance of clobazam in temporal lobe epilepsy. *Acta Neurological Scandinavica*, *93*(2-3), 88–93
3) Bartolomei, F., Chauvel, P., & Wendling, F. (2008). Epileptogenicity of brain structures in human temporal lobe epilepsy: A quantified study from intracerebral EEG. *Brain*, *131*(7), 1818–1830.
4) Belete, T. M. (2023). Recent progress in the development of new antiepileptic drugs with novel targets. *Annals of Neurosciences*, *30*(4), 262–276.
5) Bell, G. S., & Sander, J. W. (2001). The epidemiology of epilepsy: The size of the problem. *Seizure*, *10*(4), 306–316.
6) Berg, A. T., Testa, F. M., Levy, S. R., & Shinnar, S. (1996). The epidemiology of epilepsy: Past, present, and future. *Neurologic Clinics*, *14*(2), 383–398.
7) Blair, R. D. (2012). Temporal lobe epilepsy semiology. *Epilepsy Research and Treatment*, 2012, 751510.
8) Chu-Shore, C. J., & Thiele, E. A. (2010). New drugs for pediatric epilepsy. *Seminars in Pediatric Neurology*, *17*(4), 214–223.
9) Conry, J. A., Ng, Y. T., Paolicchi, J. M., Kernitsky, L., Mitchell, W. G., Ritter, F. J., et al. (2009). Clobazam in the treatment of Lennox-Gastaut syndrome. *Epilepsia*, *50*(5), 1158–1166.
10) File, S. E., & Wilks, L. J. (1990). Changes in seizure threshold and aggression during chronic treatment with three anticonvulsants and on drug withdrawal. *Psychopharmacology (Berl)*, *100*(2), 237–242.
11) Gauthier, A. C., & Mattson, R. H. (2015). Clobazam: A safe, efficacious, and newly rediscovered therapeutic for epilepsy. *CNS Neuroscience & Therapeutics*, *21*(7), 543–548.
12) Gidal, B., & Detyniecki, K. (2022). Rescue therapies for seizure clusters: Pharmacology and targets of treatments. *Epilepsia*, *63*(Suppl 1), S34–S44.
13) Golub, V., Ramakrishnan, S., & Reddy, D. S. (2023). Isobolographic analysis of adjunct antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. *Experimental Neurology*, *360*, 114294.
14) Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. (1993). *Epilepsia*, *34*(4), 592–596.
15) Joshi, R., Tripathi, M., Gupta, P., & Gupta, Y. K. (2014). Effect of clobazam as an add-on antiepileptic drug in patients with epilepsy. *Indian Journal of Medical Research*, *140*(2), 209–215.

16) Klehm, J., Thome-Souza, S., Sánchez Fernández, I., Bergin, A. M., Bolton, J., Harini, C., et al. (2014). Clobazam: Effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. *Pediatric Neurology*, *51*(1), 60–66.

17) Klotz, J., Porter, B. E., Colas, C., Schlessinger, A., & Pajor, A. M. (2016). Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay. *Molecular Medicine*, *22*, 310–321.

18) Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., et al. (2010). Definition of drug-resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*, *51*(6), 1069–1077.

19) Lee, S. (2014). Old versus new: Why do we need new antiepileptic drugs? *Journal of Epilepsy Research*, *4*, 39–44.

20) Mahmoud, S. H., & Rans, C. (2018). Systematic review of clobazam use in patients with status epilepticus. *Epilepsia Open*, *3*(3), 323–330.

21) Montenegro, M. A., & Guerreiro, C. A. (2003). Role of clobazam in the treatment of epilepsies. *Expert Review of Neurotherapeutics*, *3*(6), 829–834.

22) Muñoz, J. J., De Salamanca, R. E., Diaz-Obregón, C., & Timoneda, F. L. (1990). The effect of clobazam on steady-state plasma concentrations of carbamazepine and its metabolites. *British Journal of Clinical Pharmacology*, *29*(6), 763–765.

23) Mudigoudar, B., Weatherspoon, S., & Wheless, J. W. (2016). Emerging antiepileptic drugs for severe pediatric epilepsies. *Seminars in Pediatric Neurology*, *23*(3), 167–17

24) Muhlhofer, W., Tan, Y. L., Mueller, S. G., & Knowlton, R. (2017). MRI-negative temporal lobe epilepsy—What do we know? *Epilepsia*, *58*(5), 727–742.

25) National Centre for Biotechnology Information. (2025). *PubChem compound summary for CID 2789, Clobazam*.

26) Ng, Y. T., Conry, J., Mitchell, W. G., Buchhalter, J., Isojarvi, J., Lee, D., et al. (2015). Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups. *Epilepsy & Behavior*, *46*, 221–226.

27) Paton, C. (2002). Benzodiazepines and disinhibition: A review. *Psychiatric Bulletin*, *26*, 460–462.

28) Patsalos, P. N., Szaflarski, J. P., Gidal, B., VanLandingham, K., Critchley, D., & Morrison, G. (2020). Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors, or common antiseizure drugs. *Epilepsia*, *61*(9), 1854–1868.

29) Perry, M. S., Bailey, L., Malik, S., Gilson, C., Kotecha, A., & Hernandez, A. (2013). Clobazam for the treatment of intractable epilepsy in children. *Journal of Child Neurology*, *28*(1), 34–39.

30) Pernea, M., & Sutcliffe, A. G. (2016). Clobazam and its use in epilepsy. *Pediatric Reports*, *8*(2), 6516.

31) Rana, R. R., Rajasekaran, K., Knappertz, V., & Gray, R. A. (2023). Pharmacodynamics' synergism contributes to the antiseizure action of cannabidiol and clobazam. *Experimental Neurology*, *360*, 114286.

32) Robertson, M. M. (1986). Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: The place of clobazam. *Epilepsia*, *27*(Suppl 1), S27–S41.

33) Rondfeldt, C., Tipold, A., & Löscher, W. (2015). Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy. *BMC Veterinary Research*, *11*, 228.

34) Russell, G. R., Phelps, S. J., Shelton, C. M., & Wheless, J. W. (2018). Impact of drug interactions on clobazam and N-desmethylclobazam concentrations in pediatric patients with epilepsy. *Therapeutic Drug Monitoring*, *40*(4), 452–462.

35) Sankar, R. (2012). GABAA receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. *CNS Drugs*, *26*(3), 229–244.

36) Sander, J. W. A. S. (1997). The epidemiology of the epilepsies: Future directions. *Epilepsia*, *38*(5), 614–618.

37) Singh, D., Kumar, P., & Narang, A. (2005). A randomised controlled trial of phenobarbital in neonates with hypoxic-ischaemic encephalopathy. *Journal of Maternal-Fetal and Neonatal Medicine*, *18*(6), 391–395.

38) Téllez-Zenteno, J. F., & Hernández-Ronquillo, L. (2012). A review of the epidemiology of temporal lobe epilepsy. *Epilepsy Research and Treatment*, 2012, 630853.

39) Tolbert, D., & Larsen, F. (2019). A comprehensive overview of the clinical pharmacokinetics of clobazam. *Journal of Clinical Pharmacology*, *59*(1), 7–19.

40) Tolbert, D., Bekersky, I., Chu, H. M., & Ette, E. I. (2016). An integrative population pharmacokinetics approach to the characterisation of the effect of hepatic impairment on clobazam pharmacokinetics. *Journal of Clinical Pharmacology*, *56*(2), 213–222.

41) Uzunhan, T. A., & Gor, Z. (2020). Efficacy and side effect profile of clobazam in children with different etiologies of epilepsy. *Şişli Etfal Hastanesi Tıp Bülteni*, *54*(2), 236–244.

42) Walzer, M., Bekersky, I., Blum, R. A., & Tolbert, D. (2012). Pharmacokinetic drug interactions between clobazam and drugs metabolised by cytochrome P450 isoenzymes. *Pharmacotherapy*, *32*(4), 340–353.

43) Wiebe, S. (2000). Epidemiology of temporal lobe epilepsy. *Canadian Journal of Neurological Sciences*, *27*(Suppl 1), S6–S10.

44) Wildin, J. D., Pleuvry, B. J., Mawer, G. E., Onon, T., & Millington, L. (1990). Respiratory and sedative effects of clobazam and clonazepam in volunteers. *British Journal of Clinical Pharmacology*, *29*(2), 169–177.